Vaccination of healthcare personnel in Europe: Update to current policies

Helena C. Maltezou; Elisabeth Botelho-Nevers; Arne B. Brantsæter; Rose Marie Carlsson; Ulrich Heininger; Judith M. Hübschen; Kamilla S. Josefsdottir; George Kassianos; Jan Kyncl; Caterina Ledda; Snežana Medić; Aneta Nitsch-Osuch; Raul Ortiz de Lejarazu; Maria Theodoridou; Pierre Van Damme; Gerrit A. van Essen; Sabine Wicker; Ursula Wiedermann; Gregory A. Poland; Silvia Bino; Radosveta Filipova; Vladimir Draženović; Maria Koliou; Katerina Fabianova; Lise Heilmann Jensen; Irina Filippova; Ulpu Elonsalo; Zsuzsanna Molnár; Kamilla Sigridur Josefsdottir; Lynda Sisson; Jurijs Perevoscikovs; Larisa Savrasova; Saulius Caplinskas; Françoise Berthet; Judith M. Hübschen; Michael Borg; Olga Cirstea; Gerrit A.van Essen; Silva Graça; Oana Falup-Pecurariu; Irina Mikheeva; Dagmar Kollárová; Tatjana Mrvic; Raúl Ortiz de Lejarazu; Adam Roth; Liudmyla Chernyshova; Fedir Lapiy; Vaccination Policies for HCP in Europe Study Group

doi:10.1016/j.vaccine.2019.09.061

Vaccination of healthcare personnel in Europe: Update to current policies

Helena C. Maltezou^*, Elisabeth Botelho-Nevers, Arne B. Brantsæter, Rose Marie Carlsson, Ulrich Heininger, Judith M. Hübschen, Kamilla S. Josefsdottir, George Kassianos, Jan Kyncl, Caterina Ledda, Snežana Medić, Aneta Nitsch-Osuch, Raul Ortiz de Lejarazu, Maria Theodoridou, Pierre Van Damme, Gerrit A. van Essen, Sabine Wicker, Ursula Wiedermann, Gregory A. Poland, Silvia BinoRadosveta Filipova, Vladimir Draženović, Maria Koliou, Katerina Fabianova, Lise Heilmann Jensen, Irina Filippova, Ulpu Elonsalo, Zsuzsanna Molnár, Kamilla Sigridur Josefsdottir, Lynda Sisson, Jurijs Perevoscikovs, Larisa Savrasova, Saulius Caplinskas, Françoise Berthet, Judith M. Hübschen, Michael Borg, Olga Cirstea, Gerrit A.van Essen, Silva Graça, Oana Falup-Pecurariu, Irina Mikheeva, Dagmar Kollárová, Tatjana Mrvic, Raúl Ortiz de Lejarazu, Adam Roth, Liudmyla Chernyshova, Fedir Lapiy, Vaccination Policies for HCP in Europe Study Group

^*Corresponding author for this work

Clinical and Applied Virology

Research output: Contribution to journal › Article › Research › peer-review

89 Citations (Scopus)

Abstract

We investigated and compared current national vaccination policies for health-care personnel (HCP) in Europe with results from our previous survey. Data from 36 European countries were collected using the same methodology as in 2011. National policies for HCP immunization were in place in all countries. There were significant differences in terms of number of vaccinations, target HCP and healthcare settings, and implementation regulations (recommended or mandatory vaccinations). Vaccination policies against hepatitis B and seasonal influenza were present in 35 countries each. Policies for vaccination of HCP against measles, mumps, rubella and varicella existed in 28, 24, 25 and 19 countries, respectively; and against tetanus, diphtheria, pertussis and poliomyelitis in 21, 20, 19, and 18 countries, respectively. Recommendations for hepatitis A immunization existed in 17 countries, and against meningococcus B, meningococcus C, meningococcus A, C, W, Y, and tuberculosis in 10, 8, 17, and 7 countries, respectively. Mandatory vaccination policies were found in 13 countries and were a pre-requisite for employment in ten. Comparing the vaccination programs of the 30 European countries that participated in the 2011 survey, we found that more countries had national vaccination policies against measles, mumps, rubella, hepatitis A, diphtheria, tetanus, poliomyelitis, pertussis, meningococcus C and/or meningococcus A, C, W, Y; and more of these implemented mandatory vaccination policies for HCP. In conclusion, European countries now have more comprehensive national vaccination programs for HCP, however there are still gaps. Given the recent large outbreaks of vaccine-preventable diseases in Europe and the occupational risk for HCP, vaccination policies need to be expanded and strengthened in several European countries. Overall, vaccination policies for HCP in Europe should be periodically re-evaluated in order to provide optimal protection against vaccine-preventable diseases and infection control within healthcare facilities for HCP and patients.

Original language	English
Pages (from-to)	7576-7584
Number of pages	9
Journal	Vaccine
Volume	37
Issue number	52
DOIs	https://doi.org/10.1016/j.vaccine.2019.09.061
Publication status	Published - 10 Dec 2019

Keywords

Europe
Healthcare personnel
Occupational
Policies
Vaccination

Access to Document

10.1016/j.vaccine.2019.09.061

Cite this

Maltezou, H. C., Botelho-Nevers, E., Brantsæter, A. B., Carlsson, R. M., Heininger, U., Hübschen, J. M., Josefsdottir, K. S., Kassianos, G., Kyncl, J., Ledda, C., Medić, S., Nitsch-Osuch, A., de Lejarazu, R. O., Theodoridou, M., Van Damme, P., van Essen, G. A., Wicker, S., Wiedermann, U., Poland, G. A., ... Vaccination Policies for HCP in Europe Study Group (2019). Vaccination of healthcare personnel in Europe: Update to current policies. Vaccine, 37(52), 7576-7584. https://doi.org/10.1016/j.vaccine.2019.09.061

@article{b7783b1050c8438ba83fe194eaf479b0,

title = "Vaccination of healthcare personnel in Europe: Update to current policies",

abstract = "We investigated and compared current national vaccination policies for health-care personnel (HCP) in Europe with results from our previous survey. Data from 36 European countries were collected using the same methodology as in 2011. National policies for HCP immunization were in place in all countries. There were significant differences in terms of number of vaccinations, target HCP and healthcare settings, and implementation regulations (recommended or mandatory vaccinations). Vaccination policies against hepatitis B and seasonal influenza were present in 35 countries each. Policies for vaccination of HCP against measles, mumps, rubella and varicella existed in 28, 24, 25 and 19 countries, respectively; and against tetanus, diphtheria, pertussis and poliomyelitis in 21, 20, 19, and 18 countries, respectively. Recommendations for hepatitis A immunization existed in 17 countries, and against meningococcus B, meningococcus C, meningococcus A, C, W, Y, and tuberculosis in 10, 8, 17, and 7 countries, respectively. Mandatory vaccination policies were found in 13 countries and were a pre-requisite for employment in ten. Comparing the vaccination programs of the 30 European countries that participated in the 2011 survey, we found that more countries had national vaccination policies against measles, mumps, rubella, hepatitis A, diphtheria, tetanus, poliomyelitis, pertussis, meningococcus C and/or meningococcus A, C, W, Y; and more of these implemented mandatory vaccination policies for HCP. In conclusion, European countries now have more comprehensive national vaccination programs for HCP, however there are still gaps. Given the recent large outbreaks of vaccine-preventable diseases in Europe and the occupational risk for HCP, vaccination policies need to be expanded and strengthened in several European countries. Overall, vaccination policies for HCP in Europe should be periodically re-evaluated in order to provide optimal protection against vaccine-preventable diseases and infection control within healthcare facilities for HCP and patients.",

keywords = "Europe, Healthcare personnel, Occupational, Policies, Vaccination",

author = "Maltezou, {Helena C.} and Elisabeth Botelho-Nevers and Brants{\ae}ter, {Arne B.} and Carlsson, {Rose Marie} and Ulrich Heininger and H{\"u}bschen, {Judith M.} and Josefsdottir, {Kamilla S.} and George Kassianos and Jan Kyncl and Caterina Ledda and Sne{\v z}ana Medi{\'c} and Aneta Nitsch-Osuch and {de Lejarazu}, {Raul Ortiz} and Maria Theodoridou and {Van Damme}, Pierre and {van Essen}, {Gerrit A.} and Sabine Wicker and Ursula Wiedermann and Poland, {Gregory A.} and Silvia Bino and Radosveta Filipova and Vladimir Dra{\v z}enovi{\'c} and Maria Koliou and Katerina Fabianova and {Heilmann Jensen}, Lise and Irina Filippova and Ulpu Elonsalo and Zsuzsanna Moln{\'a}r and {Sigridur Josefsdottir}, Kamilla and Lynda Sisson and Jurijs Perevoscikovs and Larisa Savrasova and Saulius Caplinskas and Fran{\c c}oise Berthet and H{\"u}bschen, {Judith M.} and Michael Borg and Olga Cirstea and Essen, {Gerrit A.van} and Silva Gra{\c c}a and Oana Falup-Pecurariu and Irina Mikheeva and Dagmar Koll{\'a}rov{\'a} and Tatjana Mrvic and {de Lejarazu}, {Ra{\'u}l Ortiz} and Adam Roth and Liudmyla Chernyshova and Fedir Lapiy and {Vaccination Policies for HCP in Europe Study Group}",

note = "Funding Information: Dr. Bino coordinates the Albanian vaccination program; Dr. Drazenovic has received travel expenses and a lecture honorarium from Sanofi Pasteur in 2018; Dr. Heininger is a member of the Global Pertussis Initiative and CEEPAG (Collaboration of European Pertussis Awareness Generation), which are both supported by an unrestricted educational grant from Sanofi Pasteur; Prof. Theodoridou is the President of the Hellenic National Vaccinations Committee; Dr. Kassianos is the National Immunisation Lead for the Royal College of General Practitioners and President of the British Global & Travel Health Association and has participated in advisory panels and lectured at meetings organised by pharmaceutical companies as well by the CDC, ESWI, NHS; Dr. Kyncl is Vice Chairman of the Expert Working Group of the Czech National Immunization Committee; Dr. Maltezou is the Coordinator of the Committee for the Promotion of Influenza Vaccination among HCPs and primary investigator in studies for which universities received funds from vaccine manufacturers; Dr. Ortiz de Lejarazu has received fees for conferences and advising from GSK, Sanofi and Seqirus; Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Dr. Poland holds patents related to vaccinia and measles peptide vaccines. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies; Prof. Van Damme is a member of the Belgian NITAG and primary investigator of a number of vaccine trials for which to university of Antwerp obtains grants from vaccine manufacturers; Dr van Essen received speaking fees and was paid for consultancy on RSV vaccinations two times in the past three years; Dr. Wicker is a Member of the German Standing Committee on Vaccination (STIKO), Robert Koch-Institute; Prof. Wiedermann is a Member of the Austrian Committee of Immunization Practise and primary investigator of clinical vaccination trials sponsored by GSK, Pfizer and Themis; Silvia Bino, Fran{\c c}oise Berthet, Elisabeth Botelho-Nevers, Arne B. Brants{\ae}ter, Saulius Caplinskas, Rose-Marie Carlsson, Liudmyla Chernyshova, Olga Cirstea, Vladimir Drazenovic, Ulpu Elonsalo, Oana Falup-Pecurariu, Irina Filippova, Radosveta Filipova, Silva Gra{\c c}a, Lise Heilmann Jensen,Judith M. H{\"u}bschen, Kamilla Josefsdottir, Maria Koliou, Dagmar Koll{\'a}rov{\'a}, Fedir Lapiy, Caterina Ledda, Helena Maltezou, Sne{\v z}ana Medi{\'c}, Irina Mikheeva, Zsuzsanna Moln{\'a}r, Tatjana Mrvic, Aneta Nitsch-Osuch, Jurijs Perevoscikovs, Adam Roth, Larisa Savrasova, Lynda Sisson: no conflict of interest. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = dec,

day = "10",

doi = "10.1016/j.vaccine.2019.09.061",

language = "English",

volume = "37",

pages = "7576--7584",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "52",

}

Maltezou, HC, Botelho-Nevers, E, Brantsæter, AB, Carlsson, RM, Heininger, U, Hübschen, JM, Josefsdottir, KS, Kassianos, G, Kyncl, J, Ledda, C, Medić, S, Nitsch-Osuch, A, de Lejarazu, RO, Theodoridou, M, Van Damme, P, van Essen, GA, Wicker, S, Wiedermann, U, Poland, GA, Bino, S, Filipova, R, Draženović, V, Koliou, M, Fabianova, K, Heilmann Jensen, L, Filippova, I, Elonsalo, U, Molnár, Z, Sigridur Josefsdottir, K, Sisson, L, Perevoscikovs, J, Savrasova, L, Caplinskas, S, Berthet, F, Hübschen, JM, Borg, M, Cirstea, O, Essen, GAV, Graça, S, Falup-Pecurariu, O, Mikheeva, I, Kollárová, D, Mrvic, T, de Lejarazu, RO, Roth, A, Chernyshova, L, Lapiy, F & Vaccination Policies for HCP in Europe Study Group 2019, 'Vaccination of healthcare personnel in Europe: Update to current policies', Vaccine, vol. 37, no. 52, pp. 7576-7584. https://doi.org/10.1016/j.vaccine.2019.09.061

TY - JOUR

T1 - Vaccination of healthcare personnel in Europe

T2 - Update to current policies

AU - Maltezou, Helena C.

AU - Botelho-Nevers, Elisabeth

AU - Brantsæter, Arne B.

AU - Carlsson, Rose Marie

AU - Heininger, Ulrich

AU - Hübschen, Judith M.

AU - Josefsdottir, Kamilla S.

AU - Kassianos, George

AU - Kyncl, Jan

AU - Ledda, Caterina

AU - Medić, Snežana

AU - Nitsch-Osuch, Aneta

AU - de Lejarazu, Raul Ortiz

AU - Theodoridou, Maria

AU - Van Damme, Pierre

AU - van Essen, Gerrit A.

AU - Wicker, Sabine

AU - Wiedermann, Ursula

AU - Poland, Gregory A.

AU - Bino, Silvia

AU - Filipova, Radosveta

AU - Draženović, Vladimir

AU - Koliou, Maria

AU - Fabianova, Katerina

AU - Heilmann Jensen, Lise

AU - Filippova, Irina

AU - Elonsalo, Ulpu

AU - Molnár, Zsuzsanna

AU - Sigridur Josefsdottir, Kamilla

AU - Sisson, Lynda

AU - Perevoscikovs, Jurijs

AU - Savrasova, Larisa

AU - Caplinskas, Saulius

AU - Berthet, Françoise

AU - Hübschen, Judith M.

AU - Borg, Michael

AU - Cirstea, Olga

AU - Essen, Gerrit A.van

AU - Graça, Silva

AU - Falup-Pecurariu, Oana

AU - Mikheeva, Irina

AU - Kollárová, Dagmar

AU - Mrvic, Tatjana

AU - de Lejarazu, Raúl Ortiz

AU - Roth, Adam

AU - Chernyshova, Liudmyla

AU - Lapiy, Fedir

AU - Vaccination Policies for HCP in Europe Study Group

N1 - Funding Information: Dr. Bino coordinates the Albanian vaccination program; Dr. Drazenovic has received travel expenses and a lecture honorarium from Sanofi Pasteur in 2018; Dr. Heininger is a member of the Global Pertussis Initiative and CEEPAG (Collaboration of European Pertussis Awareness Generation), which are both supported by an unrestricted educational grant from Sanofi Pasteur; Prof. Theodoridou is the President of the Hellenic National Vaccinations Committee; Dr. Kassianos is the National Immunisation Lead for the Royal College of General Practitioners and President of the British Global & Travel Health Association and has participated in advisory panels and lectured at meetings organised by pharmaceutical companies as well by the CDC, ESWI, NHS; Dr. Kyncl is Vice Chairman of the Expert Working Group of the Czech National Immunization Committee; Dr. Maltezou is the Coordinator of the Committee for the Promotion of Influenza Vaccination among HCPs and primary investigator in studies for which universities received funds from vaccine manufacturers; Dr. Ortiz de Lejarazu has received fees for conferences and advising from GSK, Sanofi and Seqirus; Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Dr. Poland holds patents related to vaccinia and measles peptide vaccines. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies; Prof. Van Damme is a member of the Belgian NITAG and primary investigator of a number of vaccine trials for which to university of Antwerp obtains grants from vaccine manufacturers; Dr van Essen received speaking fees and was paid for consultancy on RSV vaccinations two times in the past three years; Dr. Wicker is a Member of the German Standing Committee on Vaccination (STIKO), Robert Koch-Institute; Prof. Wiedermann is a Member of the Austrian Committee of Immunization Practise and primary investigator of clinical vaccination trials sponsored by GSK, Pfizer and Themis; Silvia Bino, Françoise Berthet, Elisabeth Botelho-Nevers, Arne B. Brantsæter, Saulius Caplinskas, Rose-Marie Carlsson, Liudmyla Chernyshova, Olga Cirstea, Vladimir Drazenovic, Ulpu Elonsalo, Oana Falup-Pecurariu, Irina Filippova, Radosveta Filipova, Silva Graça, Lise Heilmann Jensen,Judith M. Hübschen, Kamilla Josefsdottir, Maria Koliou, Dagmar Kollárová, Fedir Lapiy, Caterina Ledda, Helena Maltezou, Snežana Medić, Irina Mikheeva, Zsuzsanna Molnár, Tatjana Mrvic, Aneta Nitsch-Osuch, Jurijs Perevoscikovs, Adam Roth, Larisa Savrasova, Lynda Sisson: no conflict of interest. Publisher Copyright: © 2019 Elsevier Ltd

PY - 2019/12/10

Y1 - 2019/12/10

N2 - We investigated and compared current national vaccination policies for health-care personnel (HCP) in Europe with results from our previous survey. Data from 36 European countries were collected using the same methodology as in 2011. National policies for HCP immunization were in place in all countries. There were significant differences in terms of number of vaccinations, target HCP and healthcare settings, and implementation regulations (recommended or mandatory vaccinations). Vaccination policies against hepatitis B and seasonal influenza were present in 35 countries each. Policies for vaccination of HCP against measles, mumps, rubella and varicella existed in 28, 24, 25 and 19 countries, respectively; and against tetanus, diphtheria, pertussis and poliomyelitis in 21, 20, 19, and 18 countries, respectively. Recommendations for hepatitis A immunization existed in 17 countries, and against meningococcus B, meningococcus C, meningococcus A, C, W, Y, and tuberculosis in 10, 8, 17, and 7 countries, respectively. Mandatory vaccination policies were found in 13 countries and were a pre-requisite for employment in ten. Comparing the vaccination programs of the 30 European countries that participated in the 2011 survey, we found that more countries had national vaccination policies against measles, mumps, rubella, hepatitis A, diphtheria, tetanus, poliomyelitis, pertussis, meningococcus C and/or meningococcus A, C, W, Y; and more of these implemented mandatory vaccination policies for HCP. In conclusion, European countries now have more comprehensive national vaccination programs for HCP, however there are still gaps. Given the recent large outbreaks of vaccine-preventable diseases in Europe and the occupational risk for HCP, vaccination policies need to be expanded and strengthened in several European countries. Overall, vaccination policies for HCP in Europe should be periodically re-evaluated in order to provide optimal protection against vaccine-preventable diseases and infection control within healthcare facilities for HCP and patients.

AB - We investigated and compared current national vaccination policies for health-care personnel (HCP) in Europe with results from our previous survey. Data from 36 European countries were collected using the same methodology as in 2011. National policies for HCP immunization were in place in all countries. There were significant differences in terms of number of vaccinations, target HCP and healthcare settings, and implementation regulations (recommended or mandatory vaccinations). Vaccination policies against hepatitis B and seasonal influenza were present in 35 countries each. Policies for vaccination of HCP against measles, mumps, rubella and varicella existed in 28, 24, 25 and 19 countries, respectively; and against tetanus, diphtheria, pertussis and poliomyelitis in 21, 20, 19, and 18 countries, respectively. Recommendations for hepatitis A immunization existed in 17 countries, and against meningococcus B, meningococcus C, meningococcus A, C, W, Y, and tuberculosis in 10, 8, 17, and 7 countries, respectively. Mandatory vaccination policies were found in 13 countries and were a pre-requisite for employment in ten. Comparing the vaccination programs of the 30 European countries that participated in the 2011 survey, we found that more countries had national vaccination policies against measles, mumps, rubella, hepatitis A, diphtheria, tetanus, poliomyelitis, pertussis, meningococcus C and/or meningococcus A, C, W, Y; and more of these implemented mandatory vaccination policies for HCP. In conclusion, European countries now have more comprehensive national vaccination programs for HCP, however there are still gaps. Given the recent large outbreaks of vaccine-preventable diseases in Europe and the occupational risk for HCP, vaccination policies need to be expanded and strengthened in several European countries. Overall, vaccination policies for HCP in Europe should be periodically re-evaluated in order to provide optimal protection against vaccine-preventable diseases and infection control within healthcare facilities for HCP and patients.

KW - Europe

KW - Healthcare personnel

KW - Occupational

KW - Policies

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85073521772&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.09.061

DO - 10.1016/j.vaccine.2019.09.061

M3 - Article

C2 - 31623916

AN - SCOPUS:85073521772

SN - 0264-410X

VL - 37

SP - 7576

EP - 7584

JO - Vaccine

JF - Vaccine

IS - 52

ER -

Vaccination of healthcare personnel in Europe: Update to current policies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this